FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W247444638> ?p ?o ?g. }

• W247444638 endingPage "60" @default.
• W247444638 startingPage "755" @default.
• W247444638 abstract "Telomerase activity is found in 85%-90% of all human cancers but not in their adjacent normal cells. Human telomerase reverse transcriptase (hTERT) is an essential component in the telomerase complex that plays an important role in telomerase activity. This study investigated the effect of the telomerase inhibition with an hTERT antisense oligodeoxynucleotide (ODN) in bladder cancer cells (T24) on tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis.Antisense phosphorothioate oligodeoxynucleotide (AS PS-ODN) was synthesized and purified. Telomerase activity was measured by polymerase chain reaction enzyme-linked immunoassay (PCR-ELISA). hTERT mRNA expression was measured by reverse transcription polymerase chain reaction (RT-PCR) assay and a gel-image system. hTERT protein was detected by immunochemistry and flow cytometry. Cell viability was measured by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium (MTT) assay. Cell apoptosis was observed by a morphological method and determined by flow cytometry.AS PS-ODN significantly inhibited telomerase activity and decreased the levels of hTERT mRNA which preceded the decline in the telomerase activity. AS PS-ODN significantly reduced the percentage of positive cells expressing hTERT protein following the decline of hTERT mRNA levels. There was no difference seen in the telomerase activity, hTERT mRNA expression or the protein levels between the sense phosphorothioate oligodeoxynucleotide (SPS-ODN) and the control group. AS PS-ODN treatment significantly decreased the cell viability and enhanced the apoptotic rate of T24 cells in response to TNF-alpha while there was no difference in cell viability and apoptotic rate between the S PS-ODN and the control group.AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression. Treatment with AS PS-ODN may be a potential and most promising strategy for bladder cancer with telomerase activity." @default.
• W247444638 created "2016-06-24" @default.
• W247444638 creator A5019988055 @default.
• W247444638 creator A5084191419 @default.
• W247444638 date "2007-05-05" @default.
• W247444638 modified "2023-09-23" @default.
• W247444638 title "Inhibition of telomerase with human telomerase reverse transcriptase antisense enhances tumor necrosis factor-alpha-induced apoptosis in bladder cancer cells." @default.
• W247444638 cites W1546807582 @default.
• W247444638 cites W1775874584 @default.
• W247444638 cites W1978006437 @default.
• W247444638 cites W1996593524 @default.
• W247444638 cites W2006877642 @default.
• W247444638 cites W2007539830 @default.
• W247444638 cites W2026856852 @default.
• W247444638 cites W2030976397 @default.
• W247444638 cites W2033488675 @default.
• W247444638 cites W2035104435 @default.
• W247444638 cites W2042377388 @default.
• W247444638 cites W2058114042 @default.
• W247444638 cites W2078786713 @default.
• W247444638 cites W2123111989 @default.
• W247444638 cites W2137889982 @default.
• W247444638 cites W2149045518 @default.
• W247444638 cites W2314273878 @default.
• W247444638 cites W2315523562 @default.
• W247444638 cites W2349104031 @default.
• W247444638 cites W2405071989 @default.
• W247444638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17531113" @default.
• W247444638 hasPublicationYear "2007" @default.
• W247444638 type Work @default.
• W247444638 sameAs 247444638 @default.
• W247444638 citedByCount "2" @default.
• W247444638 crossrefType "journal-article" @default.
• W247444638 hasAuthorship W247444638A5019988055 @default.
• W247444638 hasAuthorship W247444638A5084191419 @default.
• W247444638 hasConcept C104317684 @default.
• W247444638 hasConcept C125593758 @default.
• W247444638 hasConcept C153911025 @default.
• W247444638 hasConcept C17991360 @default.
• W247444638 hasConcept C190283241 @default.
• W247444638 hasConcept C203014093 @default.
• W247444638 hasConcept C2780783641 @default.
• W247444638 hasConcept C502942594 @default.
• W247444638 hasConcept C53227056 @default.
• W247444638 hasConcept C553184892 @default.
• W247444638 hasConcept C55493867 @default.
• W247444638 hasConcept C86803240 @default.
• W247444638 hasConcept C94581717 @default.
• W247444638 hasConceptScore W247444638C104317684 @default.
• W247444638 hasConceptScore W247444638C125593758 @default.
• W247444638 hasConceptScore W247444638C153911025 @default.
• W247444638 hasConceptScore W247444638C17991360 @default.
• W247444638 hasConceptScore W247444638C190283241 @default.
• W247444638 hasConceptScore W247444638C203014093 @default.
• W247444638 hasConceptScore W247444638C2780783641 @default.
• W247444638 hasConceptScore W247444638C502942594 @default.
• W247444638 hasConceptScore W247444638C53227056 @default.
• W247444638 hasConceptScore W247444638C553184892 @default.
• W247444638 hasConceptScore W247444638C55493867 @default.
• W247444638 hasConceptScore W247444638C86803240 @default.
• W247444638 hasConceptScore W247444638C94581717 @default.
• W247444638 hasIssue "9" @default.
• W247444638 hasLocation W2474446381 @default.
• W247444638 hasOpenAccess W247444638 @default.
• W247444638 hasPrimaryLocation W2474446381 @default.
• W247444638 hasRelatedWork W1970170787 @default.
• W247444638 hasRelatedWork W2264187340 @default.
• W247444638 hasRelatedWork W2355838360 @default.
• W247444638 hasRelatedWork W2377581951 @default.
• W247444638 hasRelatedWork W2388968787 @default.
• W247444638 hasRelatedWork W2409333146 @default.
• W247444638 hasRelatedWork W2410503930 @default.
• W247444638 hasRelatedWork W2789732421 @default.
• W247444638 hasRelatedWork W3030156323 @default.
• W247444638 hasRelatedWork W3032579496 @default.
• W247444638 hasVolume "120" @default.
• W247444638 isParatext "false" @default.
• W247444638 isRetracted "false" @default.
• W247444638 magId "247444638" @default.
• W247444638 workType "article" @default.